Nanobiotix is trading 7.3% up today at $41.78. - Portzamparc initiated a 'Buy' rating on the stock today, July 10, 2026, with a target price of €56.00, suggesting over 55% upside. - This new analyst coverage builds on continued positive investor reaction to promising Phase 2 data for JNJ-1900 (NBTXR3) in stage III inoperable non-small cell lung cancer, which was presented at ESTRO 2026.